Published in Diabetes Obes Metab on December 03, 2012
Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes Care (2014) 2.04
Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. J Diabetes Investig (2013) 1.46
A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet (2014) 1.16
Insulin degludec: pharmacokinetics in patients with renal impairment. Clin Pharmacokinet (2014) 1.15
Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes Ther (2014) 1.05
Insulin degludec improves health-related quality of life (SF-36® ) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials. Diabet Med (2013) 0.96
Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment. Clin Drug Investig (2014) 0.93
Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials. Drugs Aging (2013) 0.92
Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab (2015) 0.92
Insulin degludec: a significant advancement in ultralong-acting Basal insulin. Diabetes Ther (2013) 0.92
A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trials. Diabetes Obes Metab (2013) 0.90
Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial. Diabetes Obes Metab (2016) 0.87
Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients. J Diabetes Investig (2015) 0.86
A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia. Diabet Med (2015) 0.85
Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state. J Diabetes Sci Technol (2014) 0.85
Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study. Diabetologia (2013) 0.84
Management of type 2 diabetes mellitus in older patients: current and emerging treatment options. Diabetes Ther (2013) 0.83
Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4. Diabetes Obes Metab (2016) 0.81
Update on the treatment of type 2 diabetes mellitus. World J Diabetes (2016) 0.79
IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test. J Diabetes Sci Technol (2015) 0.78
Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study). Diabetes Obes Metab (2016) 0.78
Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials. Diabetes Obes Metab (2016) 0.78
A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus. Drugs R D (2016) 0.77
Concepts and clinical use of ultra-long basal insulin. Diabetol Metab Syndr (2016) 0.77
Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes. Diabetes Obes Metab (2014) 0.76
Mechanisms of hypoglycemia unawareness and implications in diabetic patients. World J Diabetes (2015) 0.76
Minimizing Hypoglycemia and Weight Gain with Intensive Glucose Control: Potential Benefits of a New Combination Therapy (IDegLira). Adv Ther (2015) 0.76
A 1-year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal-bolus insulin therapy (Kumamoto Insulin Degludec Observational study). J Diabetes Investig (2016) 0.75
Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes. Diabetes Metab Syndr Obes (2015) 0.75
Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective. Diabetes Ther (2016) 0.75
Insulin Degludec 200 Units/mL Is Associated With Lower Injection Frequency and Improved Patient-Reported Outcomes Compared With Insulin Glargine 100 Units/mL in Patients With Type 2 Diabetes Requiring High-Dose Insulin. Clin Diabetes (2017) 0.75
Glycemic Control in a Real-Life Setting in Patients with Type 2 Diabetes Treated with IDegLira at a Single Swiss Center. Diabetes Ther (2017) 0.75
Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus. Diabetes Ther (2017) 0.75
Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes. Expert Rev Endocrinol Metab (2015) 0.75
Safety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: A first-year report from Japan. J Diabetes Investig (2015) 0.75
Modern basal insulin analogs: An incomplete story. Indian J Endocrinol Metab (2014) 0.75
Patient safety and minimizing risk with insulin administration - role of insulin degludec. Drug Healthc Patient Saf (2014) 0.75
Controlled release of biologics for the treatment of type 2 diabetes. J Control Release (2015) 0.75
Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Diabetes Obes Metab (2016) 0.75
Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus. Ther Adv Chronic Dis (2015) 0.75
Cardiovascular effects of basal insulins. Drug Healthc Patient Saf (2015) 0.75
United States experience of insulin degludec alone or in combination for type 1 and type 2 diabetes. Drug Des Devel Ther (2017) 0.75
Insulin Degludec in Clinical Practice: A Review of Japanese Real-World Data. Diabetes Ther (2017) 0.75
Concentrated insulins: the new basal insulins. Ther Clin Risk Manag (2016) 0.75
New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin. Curr Diab Rep (2017) 0.75
[Diabetic emergencies : Hypoglycemia, ketoacidotic and hyperglycemic hyperosmolar nonketotic coma]. Internist (Berl) (2017) 0.75
Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes. Diabetes Ther (2017) 0.75
Efficacy and Safety of Insulin Degludec for Hyperglycemia Management in Noncritical Hospitalized Patients with Diabetes: An Observational Study. Diabetes Ther (2017) 0.75
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med (2005) 27.77
The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care (2003) 7.80
Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia (2002) 6.00
The barrier of hypoglycemia in diabetes. Diabetes (2008) 4.50
A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care (2006) 3.91
Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev (2007) 3.69
Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab (2012) 3.68
Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res (2012) 3.29
Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab (2012) 3.06
Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care (2012) 2.89
Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care (2011) 2.60
The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health (2011) 1.92
A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care (2010) 1.50
Hypoglycemia rates with basal insulin analogs. Diabetes Technol Ther (2011) 1.14
Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. Postgrad Med (2012) 1.08
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (2006) 15.32
Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine (1999) 9.70
Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA (2001) 8.80
An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods (2001) 6.68
1998 clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association. CMAJ (1998) 4.95
Prevalence proportion ratios: estimation and hypothesis testing. Int J Epidemiol (1998) 4.73
Interpreting parameters in the logistic regression model with random effects. Biometrics (2000) 3.64
Ramipril and the development of diabetes. JAMA (2001) 3.38
Stability of insulin lispro in insulin infusion systems. Diabetes Care (1997) 3.16
CD226 Gly307Ser association with multiple autoimmune diseases. Genes Immun (2008) 2.76
The prevalence of NIDDM and associated risk factors in native Canadians. Diabetes Care (1997) 2.68
Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia (2010) 2.65
Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care (2001) 2.57
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab (2012) 2.44
Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled Type 1 diabetes; a randomized controlled trial. Diabet Med (2011) 2.39
Validation of an algorithm combining haemoglobin A(1c) and fasting plasma glucose for diagnosis of diabetes mellitus in UK and Australian populations. Diabet Med (2009) 2.38
Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. Diabetes Care (2000) 2.34
The use of real-time reverse transcriptase PCR for the quantification of cytokine gene expression. J Biomol Tech (2003) 2.30
Use of ethnographic methods for applied research on diabetes among the Ojibway-Cree in northern Ontario. Health Educ Q (1996) 2.16
Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion. Diabetologia (2008) 2.15
Maternal triglyceride levels and newborn weight in pregnant women with normal glucose tolerance. Diabet Med (2005) 2.10
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract (2013) 2.09
Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. Endocrinology (2000) 2.08
Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab (2007) 2.06
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab (2009) 2.04
Serum haptoglobin: a novel marker of adiposity in humans. J Clin Endocrinol Metab (2004) 1.94
Molecular cloning of Xenopus fibrillarin, a conserved U3 small nuclear ribonucleoprotein recognized by antisera from humans with autoimmune disease. Mol Cell Biol (1990) 1.91
Intensive insulin therapy with insulin lispro: a randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection. Diabetes Care (2001) 1.88
Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial. Diabet Med (2013) 1.84
Overweight among children and adolescents in a Native Canadian community: prevalence and associated factors. Am J Clin Nutr (2000) 1.76
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab (2010) 1.76
Multidrug-resistant tuberculosis in prison inmates, Azerbaijan. Emerg Infect Dis (2001) 1.75
Obesity and insulin resistance in humans: a dose-response study. Metabolism (1990) 1.74
Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients. Diabetologia (2005) 1.71
Insulins today and beyond. Lancet (2001) 1.71
A telemedicine support for diabetes management: the T-IDDM project. Comput Methods Programs Biomed (2002) 1.69
Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Proc Natl Acad Sci U S A (1996) 1.65
First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons. Lancet (1999) 1.64
Type 2 diabetes mellitus worsens arterial stiffness in hypertensive patients through endothelial dysfunction. Diabetologia (2012) 1.63
Diabetes mellitus and female sexuality: a review of 25 years' research. Diabet Med (1998) 1.62
Serum immunoreactive leptin concentrations in a Canadian aboriginal population with high rates of NIDDM. Diabetes Care (1997) 1.55
Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. Eur J Clin Invest (2001) 1.54
Specific patterns of food consumption and preparation are associated with diabetes and obesity in a Native Canadian community. J Nutr (1998) 1.53
Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones. Diabetologia (2008) 1.50
The hepatic nuclear factor-1alpha G319S variant is associated with early-onset type 2 diabetes in Canadian Oji-Cree. J Clin Endocrinol Metab (1999) 1.50
Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab (2009) 1.49
Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab (2011) 1.48
Roles of glucose transport and glucose phosphorylation in muscle insulin resistance of NIDDM. Diabetes (1996) 1.46
In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine. Diabet Med (2008) 1.46
IL-1beta and IFN-gamma induce the expression of diverse chemokines and IL-15 in human and rat pancreatic islet cells, and in islets from pre-diabetic NOD mice. Diabetologia (2003) 1.41
Fasting hyperglycaemia following trans-catheter arterial chemo-embolization for hepatocellular carcinoma in cirrhosis. Ital J Gastroenterol Hepatol (1997) 1.39
Intermediate metabolism in normal pregnancy and in gestational diabetes. Diabetes Metab Res Rev (2003) 1.37
Effects of weight loss in massive obesity on insulin and C-peptide dynamics: sequential changes in insulin production, clearance, and sensitivity. J Clin Endocrinol Metab (1987) 1.37
Transmembrane glucose transport in skeletal muscle of patients with non-insulin-dependent diabetes. J Clin Invest (1993) 1.34
Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab (2012) 1.34
Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes. A systematic review and meta-analysis. Diabetes Care (1999) 1.33
Hepatic glucose production is regulated both by direct hepatic and extrahepatic effects of insulin in humans. Diabetes (1996) 1.31
Protein kinase NII and the regulation of rDNA transcription in mammalian cells. Nucleic Acids Res (1989) 1.31
Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial. Diabetes Obes Metab (2013) 1.30
Monocyte chemoattractant protein-1 is expressed in pancreatic islets from prediabetic NOD mice and in interleukin-1 beta-exposed human and rat islet cells. Diabetologia (2001) 1.28
Deletion of the last two exons of the mitochondrial nad7 gene results in lack of the NAD7 polypeptide in a Nicotiana sylvestris CMS mutant. Mol Gen Genet (1995) 1.28
Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes (1999) 1.28
Common and rare ABCA1 variants affecting plasma HDL cholesterol. Arterioscler Thromb Vasc Biol (2000) 1.27
Prevalence and risk factors for gestational diabetes assessed by universal screening. Diabetes Res Clin Pract (2003) 1.27
Contribution of single nucleotide polymorphisms within FCRL3 and MAP3K7IP2 to the pathogenesis of Graves' disease. J Clin Endocrinol Metab (2005) 1.27
Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract (2005) 1.27
Early up-regulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model. Clin Exp Immunol (2004) 1.26
Alternative routes of insulin delivery. Diabet Med (2003) 1.24
A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. Diabet Med (2006) 1.24
Body image concepts differ by age and sex in an Ojibway-Cree community in Canada. J Nutr (1996) 1.22
Restriction of interferon gamma responsiveness and basal expression of the myeloid human Fc gamma R1b gene is mediated by a functional PU.1 site and a transcription initiator consensus. J Exp Med (1994) 1.22
Glucose tolerance is negatively associated with circulating progenitor cell levels. Diabetologia (2007) 1.21
1alpha,25-dihydroxyvitamin D3 induces an autoantigen-specific T-helper 1/T-helper 2 immune shift in NOD mice immunized with GAD65 (p524-543). Diabetes (2000) 1.20
Physical activity, physical fitness, and insulin and glucose concentrations in an isolated Native Canadian population experiencing rapid lifestyle change. Diabetes Care (2001) 1.20
Physical exposure assessment in monotonous repetitive work--the PRIM study. Scand J Work Environ Health (2001) 1.19
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab (2014) 1.18
Association between type 1 diabetes and GWAS SNPs in the southeast US Caucasian population. Genes Immun (2011) 1.18
Prevention of experimental colitis in SCID mice reconstituted with CD45RBhigh CD4+ T cells by blocking the CD40-CD154 interactions. J Immunol (2000) 1.17
Normalization of glycemia in diabetics during meals with insulin and glucagon delivery by the artificial pancreas. Diabetes (1977) 1.17
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Diabetes Metab (2007) 1.17
The private hepatocyte nuclear factor-1alpha G319S variant is associated with plasma lipoprotein variation in Canadian Oji-Cree. Arterioscler Thromb Vasc Biol (2000) 1.16
Male-to-female excess in diabetes diagnosed in early adulthood is not specific for the immune-mediated form nor is it HLA-DQ restricted: possible relation to increased body mass index. Diabetologia (2001) 1.16
Increasing rates of ischemic heart disease in the native population of Ontario, Canada. Arch Intern Med (2000) 1.15
Adiponectin and beta cell dysfunction in gestational diabetes: pathophysiological implications. Diabetologia (2005) 1.15
Mechanism and potential of the growth-inhibitory actions of vitamin D and ana-logs. Curr Med Chem (2007) 1.15
The metabolic syndrome is related to albuminuria in Type 2 diabetes. Diabet Med (2008) 1.14
Genome-wide scanning for type 2 diabetes susceptibility in Canadian Oji-Cree, using 190 microsatellite markers. J Hum Genet (1999) 1.14
FIRI: fasting or false insulin resistance index? Lancet (1996) 1.13
Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. Diabetes Care (2000) 1.12
Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia (2003) 1.12
Identification and immune regulation of 25-hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages. Clin Exp Immunol (2000) 1.10
Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial. Diabetologia (2011) 1.10
Type 2 diabetes in primary care in belgium: need for structured shared care. Exp Clin Endocrinol Diabetes (2009) 1.10
Effects of glucosamine infusion on insulin secretion and insulin action in humans. Diabetes (2000) 1.10
Decreased high-molecular-weight adiponectin in gestational diabetes: implications for the pathophysiology of Type 2 diabetes. Diabet Med (2007) 1.09
Involvement of 4-1BB (CD137)-4-1BBligand interaction in the modulation of CD4 T cell-mediated inflammatory colitis. Clin Exp Immunol (2006) 1.09
Role of tissue-specific blood flow and tissue recruitment in insulin-mediated glucose uptake of human skeletal muscle. Circulation (1998) 1.08